Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa

Today, Scandinavian Biopharma reports on encouraging new results from a Phase 2b study of the oral, inactivated vaccine candidate ETVAX® against enterotoxigenic Escherichia coli (ETEC), the most frequent cause of travelers’ diarrhea and enteric illness among infants and young children in low-resource settings. The trial enrolled adult volunteers from Finland who travelled to Grand Popo, […]